Rethinking What To Call The ‘Real World’
Stakeholders suggest a host of alternatives to what they see as the US FDA’s poor choice of words to describe studies intended to reflect actual clinical practice.
Stakeholders suggest a host of alternatives to what they see as the US FDA’s poor choice of words to describe studies intended to reflect actual clinical practice.